MBX Biosciences, Inc. was incorporated in August 2018 as an Indiana limited liability company and converted to a Delaware corporation in April 2019. The company is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel precision peptide therapeutics for endocrine and metabolic disorders. Its pipeline includes drug candidates for hypoparathyroidism, obesity, and post-bariatric hypoglycemia, designed using its proprietary Precision Endocrine Peptide (PEP) platform.